Showing 2961-2970 of 5621 results for "".
- Scientists Develop Therapeutic Model for Potentially Treating Incurable Eye Diseaseshttps://modernod.com/news/scientists-develop-therapeutic-model-for-potentially-treating-incurable-eye-diseases/2481794/Researchers have successfully transplanted human microglia cells into mouse retina to create a model that could be used to test new treatments for retinal and central nervous system diseases, according to not-for-profit eLife. Microglia are the innate immune cells of the cent
- Regeneron Expects FDA Decision on High-Dose Aflibercept in Third Quarterhttps://modernod.com/news/regeneron-expects-fda-decision-on-high-dose-eylea-in-third-quarter/2481766/During its second quarter conference call, Regeneron said it anticipates the FDA will take action on its biologics license application (BLA) for high-dose aflibercept during the third quarter. In June, citing "an ongoing review of inspection findings at a third-party filler,"
- Glaucoma Treatment Research at Missouri S&T Receives NIH Fundinghttps://modernod.com/news/glaucoma-treatment-research-at-missouri-st-receives-nih-funding/2481759/The Missouri University of Science and Technology (S&T) announced that the National Institutes for Health (NIH) has awarded an R01 grant to Professor Hu Yang, PhD, who is S&T’s Doshi Endowed Department Chair of Chemical and Biochemical Engineering. The grant will prov
- Optometry and Vision Science Names New Editor-in-Chiefhttps://modernod.com/news/optometry-and-vision-science-announces-new-editor-in-chief/2481744/The American Academy of Optometry (AAO) announced that David Elliott, PhD, FCOptom, FAAO, is the new editor-in-chief of Optometry and Vision Science (OVS). Mr. Elliott succeeds Michael Twa, OD, PhD, FAAO, who is stepping down from the role after 7 years.
- Study: Dietary Oral Zeaxanthin Decreases the Progression of Wet AMDhttps://modernod.com/news/study-dietary-oral-zeaxanthin-decreases-the-progression-of-wet-amd/2481741/Data published in the peer-reviewed journal Ophthalmology and Therapy confirmed both an earlier comparative
- Allotex Secures Funding for Allogeneic Presbyopia Inlayshttps://modernod.com/news/allotex-secures-funding-for-allogeneic-presbyopia-inlays/2481717/Allotex and SpA announced the first close of its $30 million Series B financing to support the further development of its technology for the treatment of refractive errors. The investment was driven by 4-year data on presbyopia and hyperopia treatments, confirming significant impro
- SpyGlass Pharma Completes $90 Million Series C Financing to Advance Novel Treatments for Glaucoma and Other Chronic Ophthalmic Diseaseshttps://modernod.com/news/spyglass-pharma-completes-90-million-series-c-financing-to-advance-novel-treatments-for-glaucoma-and-other-chronic-ophthalmic-diseases/2481711/SpyGlass Pharma announced the closing of $90 million in Series C financing to enable the company to conduct multiple US clinical trials of SpyGlass’ drug delivery platform. The SpyGlass system has the potential to deliver multiple years of medical therapy to address significant unmet n
- Salvat Laboratories Initiates a Pediatric Study in Europe with SVT-15473 for the Treatment of Inflammation and Pain Following Ocular Surgeryhttps://modernod.com/news/salvat-laboratories-initiates-a-pediatric-study-in-europe-with-svt-15473-for-the-treatment-of-inflammation-and-pain-following-ocular-surgery/2481707/Salvat Laboratories has initiated a new study with SVT-15473 clobetasol to treat inflammation and pain in patients undergoing ocular surgery. The trial will include children aged 0 to 3 years with cataracts, aiming to demonstrate the drug's safety in this population. Cataracts
- Mount Sinai Launches Center for Ophthalmic Artificial Intelligence and Human Healthhttps://modernod.com/news/mount-sinai-launches-center-for-ophthalmic-artificial-intelligence-and-human-health/2481706/The Icahn School of Medicine at Mount Sinai has launched the Center for Ophthalmic Artificial Intelligence and Human Health, the first-of-its-kind in New York and one of the first in the United States. The Center is dedicated to advancing artificial intelligence (AI) in the field of ophthalm
- Gamesquare Partners with Vivior to Help Gamers Build Healthy Screen Habitshttps://modernod.com/news/gamesquare-partners-with-vivior-to-help-gamers-build-healthy-screen-habits/2481646/GameSquare Holdings announced a multi-year, multi-million dollar partnership with Swiss vision care startup Vivior with the aim of promoting healthy digital habits, according to a company news release. Through content creation, product development, and competition, GameSquare and Vivior